Hospira, Inc. v. Fresenius Kabi USA, LLC, No. 19-1329 (Fed. Cir. Jan. 9, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Hospira Inc. (“Hospira”) appeals from the judgment of the United States District Court for the Northern District of Illinois that claim 6 of U.S. Patent 8,648,106 (“the ’106 patent”) is invalid as obvious. Hospira, Inc. v. Fresenius Kabi U SA, LLC , 343 F. Supp. 3d 823 (N.D. Ill. 2018) (“Opinion”). Because we find that the district court’s fac- tual findings were not clearly erroneous and that those findings support a conclusion of obviousness, we affirm.